Wisconsin Alumni Research Foundation
A Leader in University Technology Transfer since 1925
Home | Printer Friendly
Technologies
New Inventions
New Patents
Agriculture (144)
Analytical Instrumentation (129)
Cleantech (89)
Diagnostic Assays (61)
Drug Discovery (164)
Education & Training (9)
Engineering (12)
Engines & Power Electronics (54)
Food & Supplements (56)
Information Technology (120)
Materials & Chemicals (94)
Medical Devices (76)
Medical Imaging (125)
Micro & Nanotech (69)
Miscellaneous (2)
Pharmaceuticals & Vitamin D (209)
Antibacterials
Antifungals
Antivirals
Biodefense
Cardiovascular
Diabetes
Immunity & auto-immune
Inflammation
Metabolic disorders
Musculoskeletal
Neurological & mental health
Ocular
Oncology & hematology
Organ & tissue transplants
Pain
Pulmonary
Reproduction & infertility
Skin & connective tissue
Vaccines
Vitamin D
Plasma Processing (25)
Pluripotent Cells (23)
Radiation Therapy (38)
Research Tools (287)
Semiconductors & Integrated Circuits (55)
Veterinary (20)
WARF: P01050US Pharmaceuticals & Vitamin D
Crystalline 1 Alpha-Hydroxyvitamin D2 and Method of Purification
INVENTORS Hector DeLuca, Rafal Sicinski, Hazel Holden, James Thoden
The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing a method of purifying 1alpha-hydroxyvitamin D2 after synthesis to obtain the compound in crystalline form.
OVERVIEW
Preparation of organic compounds, such as 1alpha-hydroxyvitamin D compounds, usually requires multiple synthetic steps, allowing many opportunities for undesirable compounds to contaminate the final product.
THE INVENTION
UW-Madison researchers have developed a method of purifying 1alpha-hydroxyvitamin D2 after synthesis to obtain the compound in crystalline form. First, a solvent (ethyl formate, ethyl acetate or a 2-propanol-hexane mixture) is boiled under an inert atmosphere. Then a product containing the 1alpha-hydroxyvitamin D2 is dissolved in the solvent. Next, the solvent and dissolved product are cooled below ambient temperature to form a precipitate of 1alpha-hydroxyvitamin D2 crystals. Finally, the 1alpha-hydroxyvitamin D2 crystals are recovered. Optionally, petroleum ether may be added to the solvent after the product is dissolved in it.
APPLICATIONS
  • Purifying 1alpha-hydroxyvitamin D2 after synthesis
KEY BENEFITS
  • Solvents have low toxicity.
  • Solvents easily removed by evaporation or other well known methods.
  • Crystals large enough to ensure recovery by filtration.
  • Provides satisfactory yield of crystals
  • Relatively low cost
  • May be used to purify a wide range of products containing 1alpha-hydroxyvitamin D2 in varying concentrations
  • Removes 1alpha-hydroxyvitamin D4, unlike column chromatography or straight-phase HPLC separation
ADDITIONAL INFORMATION
For More Information About the Inventors
Intellectual Property Status
Tech Fields
Pharmaceuticals & Vitamin D - Vitamin D
Research Tools - Synthesis & purification
CONTACT INFORMATION
For current licensing status, please contact our team at licensing@warf.org or phone 608.262.4924. (Clicking this link will open a contact form in a popup window. If you have problems viewing the form, try disabling your popup blocker software.)
WARF Medal of Technology Since its founding in 1925 as the patenting and licensing organization for the University of Wisconsin-Madison, WARF has been working with business and industry to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.


Contact Us | WARF Extranet | Privacy Policy | IMS Powered